Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064694 | 1.00 | GPR35 (0.50) | GPR35MAPTLMNAMEN1KMT2A | |
| SCHEMBL13101313 | 0.93 | GPR35 (0.47) | GPR35MAPTLMNAMEN1KMT2A | |
| SCHEMBL3057079 | 0.85 | MEN1 (0.41) | GPR35MAPTLMNAMEN1KMT2A | |
| SCHEMBL3057078 | 0.85 | MEN1 (0.41) | GPR35MAPTLMNAMEN1KMT2A | |
| SCHEMBL4493918 | 0.81 | MAPT (0.45) | GPR35MAPTLMNAMEN1KMT2A | |
| SCHEMBL4494650 | 0.81 | MAPT (0.45) | GPR35MAPTLMNAMEN1KMT2A | |
| SCHEMBL4493919 | 0.81 | MAPT (0.45) | GPR35MAPTLMNAMEN1KMT2A | |
| SCHEMBL18512326 | 0.80 | ALDH1A1 (0.47) | GPR35MAPTLMNAMEN1KMT2A | |
| SCHEMBL13101067 | 0.79 | MEN1 (0.39) | GPR35MAPTLMNAMEN1KMT2A | |
| SCHEMBL3069073 | 0.76 | AKR1C3 (0.42) | GPR35LMNAALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889722-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2184279-B1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | SHIONOGI & CO (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8530668-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20130217885-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | SHIONOGI & CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20100267783-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2010-10-21 | — | — | US | disclosed |
| EP-2184279-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | Shionogi&Co., Ltd. (JP) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267783-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | MPL, TEK, THPO | GPR35 138/4885MAPT 4223/4885LMNA 4586/4885 |
| US-20130217885-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | MPL, TEK, THPO | GPR35 131/4885MAPT 4223/4885LMNA 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.